Sex-Dimorphic Hemoglobin Thresholds and Cardiovascular Vulnerability in Chronic Obstructive Pulmonary Disease: Molecular Mechanisms and Mortality Risk

Abstract

Anemia is a critical extrapulmonary manifestation of chronic obstructive pulmonary disease (COPD) that accelerates systemic morbidity and elevates all-cause and cardiovascular mortality. Recent epidemiological data highlight distinct clinical risk profiles associated with specific hemoglobin (Hb) cutoffs, notably 12.5 g/dL and 13.0 g/dL. Pathophysiological drive in this setting stems from chronic low-grade inflammation—mediated by interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)—which upregulates hepatic hepcidin, causes ferroportin degradation, and induces functional iron deficiency. Concurrently, arterial hypoxemia triggers hypoxia-inducible factor (HIF) pathways, but renal erythropoietin resistance impairs erythropoietic compensation. The resulting decrement in arterial oxygen content ($CaO_2$) enforces a hyperdynamic cardiovascular state, precipitating myocardial strain, endothelial nitric oxide synthase (eNOS) uncoupling, and cardiomyocyte mitochondrial uncoupling. Crucially, the diagnostic fidelity of fixed Hb thresholds is modulated by biological sex. Androgen-driven suppression of hepcidin and estrogenic regulation of systemic inflammation establish distinct physiological baselines between male and female patients. Implementing sex-and-gender-based analysis (SGBA) reveals that sub-threshold Hb levels (12.5–13.0 g/dL) represent distinct cardiovascular risk trajectories across sexes. Refining Hb thresholds with sex-stratified precision is imperative for optimizing clinical risk prediction and guiding targeted therapeutic interventions in COPD.

Introduction & Cellular Mechanisms

Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a multisystem disease characterized by chronic pulmonary and vascular inflammation. Among its systemic sequelae, secondary anemia and sub-clinical decrements in hemoglobin (Hb) concentration serve as potent, independent predictors of functional decline, acute exacerbations, and all-cause and cardiovascular mortality.

The molecular etiology of anemia in COPD involves a multi-factorial network centered on inflammatory iron sequestration and dysregulated erythropoiesis:

```
[Systemic COPD Inflammation: IL-6, TNF-α]
│
▼
[JAK2/STAT3 Activation in Liver]
│
▼
[Hepcidin Upregulation] ──► [Ferroportin Internalization/Degradation]
│
▼
[Macrophage Iron Trapping & Impaired Absorption]
│
▼
[Anemia of Chronic Disease / Functional Iron Deficiency]
│
▼
[Reduced CaO2 & Compensatory Hyperdynamic State]
│
▼
[Cardiomyocyte Stress & Adverse Remodeling]
```

1. The Hepcidin-Ferroportin Axis and Inflammatory Sequestration: Systemic inflammation driven by elevated circulating cytokines—specifically IL-6, TNF-α, and IL-1β—activates hepatic Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling. This cascade upregulates transcription of *HAMP*, the gene encoding hepcidin. Elevated systemic hepcidin binds directly to the sole cellular iron exporter, ferroportin-1, inducing its internalization and lysosomal degradation. Consequently, dietary iron absorption in duodenal enterocytes is blocked, and recycled iron is trapped within reticuloendothelial macrophages, culminating in functional iron deficiency despite adequate total-body iron stores.
2. Hypoxia-Inducible Factors and Erythropoietin Resistance: In healthy physiology, localized renal tissue hypoxia stabilizes hypoxia-inducible factor 2-alpha (HIF-2α), driving renal erythropoietin (EPO) synthesis. However, in COPD, sustained systemic inflammation impairs EPO responsiveness within bone marrow erythroid progenitor cells through downstream suppressor of cytokine signaling 3 (SOCS3) induction. This results in blunted erythropoietic expansion relative to the degree of ambient hypoxemia.
3. Cardiovascular Energetics and Organelle Dysfunction: Reductions in Hb toward or below critical thresholds (e.g., 12.5 g/dL and 13.0 g/dL) compromise arterial oxygen content ($CaO_2 = [\text{Hb}] \times 1.34 \times SaO_2 + 0.0031 \times PaO_2$). To preserve peripheral tissue $DO_2$ (oxygen delivery), the cardiovascular system triggers compensatory neurohormonal activation, increasing heart rate and stroke volume. This chronic hyperdynamic state elevates left ventricular end-diastolic pressure and myocardial wall stress. At the sub-cellular level, chronic anemic hypoxia induces mitochondrial uncoupling within cardiomyocytes, altering complex I and IV activity in the electron transport chain, increasing mitochondrial reactive oxygen species (mROS) generation, and impairing ATP synthesis. Furthermore, localized tissue hypoxia disrupts endothelial nitric oxide synthase (eNOS) phosphorylation, inducing eNOS uncoupling and exacerbating systemic vascular stiffness and microvascular rarefaction.

Sex-Dimorphic Regulation & Translational Implications

Biological sex fundamentally modulates red blood cell homeostasis, cardiovascular architecture, and inflammatory responses. Standardized, sex-agnostic evaluations of anemia fail to capture distinct underlying pathophysiological trajectories, necessitating a dedicated sex-and-gender-based analysis (SGBA).

```
[Biological Sex Modulation]
│
┌─────────────────────────┴─────────────────────────┐
▼ ▼
[Male Endocrine Profile] [Female Endocrine Profile]
- High Testosterone - Estrogen Modulation
- Hepcidin Suppression - Downregulated Marrow Kinetics
- Enhanced EPO Sensitivity - Distinct Post-Menopausal Inflammaging
│ │
▼ ▼
[Higher Normal Hb Baseline] [Lower Normal Hb Baseline]
│ │
└─────────────────────────┬─────────────────────────┘
│
▼
[Differential Cardioprotective/Pathological Thresholds]
(12.5 g/dL vs. 13.0 g/dL Risk Mapping)
```

1. Endocrine Control of Erythropoiesis:
* Androgen Actions: Testosterone exerts a direct stimulatory effect on bone marrow erythropoiesis by enhancing EPO gene transcription and downregulating hepatic hepcidin expression via suppression of the BMP/SMAD pathway. Consequently, males maintain a higher physiological baseline Hb concentration.
* Estrogen Actions: Estrogen modulates bone marrow erythroid progenitor sensitivity and dampens baseline systemic inflammatory pathways. In post-menopausal female COPD patients, loss of 17β-estradiol is accompanied by accelerated "inflammaging," leading to increased susceptibility to IL-6-driven iron sequestration and decreased baseline Hb levels.

2. Threshold Mechanics (12.5 g/dL vs. 13.0 g/dL) and Risk Misclassification:
* Conventional WHO guidelines define anemia as $\text{Hb} < 12.0\text{ g/dL}$ for females and $< 13.0\text{ g/dL}$ for males. However, intermediate thresholds (12.5 g/dL vs. 13.0 g/dL) demonstrate distinct cardiovascular risk gradients in COPD cohorts.
* A Hb of 12.5 g/dL in a male patient represents a significant drop from physiological baseline, corresponding to occult inflammatory iron sequestration, functional EPO resistance, and early hyperdynamic myocardial stress.
* Conversely, in female patients, a Hb of 12.5 g/dL may fall near standard reference intervals, yet when coupled with COPD-associated pulmonary hypertension and right ventricular strain, even minor drops below 13.0 g/dL can deplete compensatory cardiac reserve. The female myocardium exhibits distinct substrate metabolic flexibility (preferring fatty acid oxidation) that is particularly sensitive to sub-clinical reductions in oxygen delivery, lowering the ischemic threshold for ventricular dysfunction.

3. Translational Precision Medicine Dimensions:
* Biomarker Panels: Clinical risk stratification must integrate sex-stratified Hb cutoffs alongside biomarkers of iron availability (soluble transferrin receptor [sTfR], reticulocyte hemoglobin equivalent [RET-He]) and systemic inflammation (high-sensitivity C-reactive protein [hsCRP], serum hepcidin).
* Targeted Therapeutics: Applying fixed thresholds across sexes risks underdiagnosing functional anemia in males or delaying early therapeutic intervention in post-menopausal females. Targeted interventions—such as HIF-prolyl hydroxylase domain (HIF-PHD) inhibitors or anti-IL-6 monoclonal antibodies—must be evaluated in clinical trials stratified by biological sex to optimize efficacy and safety profiles.

Conclusions & Clinical Outlook

Hemoglobin levels hovering at or below critical boundaries of 12.5 g/dL and 13.0 g/dL serve as biological indicators of systemic inflammatory stress, severe cellular hypoxia, and heightened cardiovascular mortality in COPD. These thresholds mark a transition point where local pulmonary dysfunction triggers systemic vascular and myocardial degradation.

Future clinical frameworks must abandon rigid, sex-blind anemia cutoffs in favor of dynamic, sex-stratified precision algorithms. Translating these insights into practice requires prospective clinical trials that incorporate biological sex as a primary variable, evaluate systemic inflammatory markers alongside Hb dynamics, and test targeted anti-inflammatory or iron-replete strategies to mitigate cardiovascular risk in COPD.

Key Insights

Inflammatory Axis: Anemia in COPD is driven by an IL-6/hepcidin-mediated iron sequestration axis coupled with impaired EPO responsiveness, leading to mitochondrial dysfunction and adverse cardiovascular strain.

Distinct Threshold Risks: Hemoglobin thresholds of 12.5 g/dL and 13.0 g/dL signal discrete sub-clinical risk states for cardiovascular remodeling and all-cause mortality that require precise monitoring.

Sex-Dimorphic Vulnerability: Hormonal regulation by testosterones and estrogens establishes distinct baseline erythropoietic and myocardial responses, necessitating sex-stratified thresholds to prevent risk misclassification and enable tailored precision therapies.

References

1. Barnes, P. J. (2018). Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. *The Lancet Respiratory Medicine*, 6(4), 287-296. https://doi.org/10.1016/S2213-2600(18)30061-0
2. Ganz, T. (2019). Anemia of inflammation. *New England Journal of Medicine*, 381(12), 1148-1157. https://doi.org/10.1056/NEJMra1804281
3. Regitz-Zagrosek, V., & Kararigas, G. (2017). Mechanistic pathways of sex differences in cardiovascular disease. *Physiological Reviews*, 97(1), 1-37. https://doi.org/10.1152/physrev.00021.2015